AAIC – speculative Alzheimer’s groups fail to catch the Aduhelm wave
Alector, Cassava and Annovis play up mixed data in dementia, but the markets aren’t buying it.
Why Glaxo should buy Biohaven
And four other potential targets that could make sense for the beleaguered group.
Pressure on Abbvie's pipeline grows
Abbvie will need more than Skyrizi and upadacitinib to fill a Humira-shaped hole, and there are a few early-stage candidates it reckons could fit the bill.
US shutdown dampens first-quarter flotations
Biopharma IPOs dipped in the opening months of 2019, but numbers look fairly healthy despite January's US government closure.
Another strong quarter from the venture world
Private biotechs received almost $4bn in venture financing in the third quarter, as the healthy financing climate showed few signs of deteriorating.
Looking outside amyloid in Alzheimer’s disease
The amyloid hypothesis of Alzheimer's has taken another battering – and some companies are finally taking a new approach.
